(Q44187537)

English

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

scientific article published on 4 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Luciano Souza Viana

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1

object named as

Ian F Tannock

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Camilla Thellenberg Karlsson

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Aude Fléchon

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Iwona Skoneczna

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Francisco Orlandi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Gwenaelle Gravis

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vsevolod Matveev

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sevil Bavbek

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Thierry Gil

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Osvaldo Arén

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Oleg Karyakin

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alison Birtle

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Emmanuelle Magherini

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Laurence Hatteville

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Daniel Petrylak

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Bertrand Tombal

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Mark Rosenthal

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

VENICE investigators

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Karim Fizazi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

4 June 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

760-768

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Designs for group sequential tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination targeted therapy in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970184-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70184-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23742877%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44187537&oldid=2108353775"